Abstract
Background Over 2.6 million babies are lost later in pregnancy, during labour, and or in the first week of life. Global perinatal mortality reduced from 5.7 million since 2000 to 4.1 million in 2015. High-income countries account for 45% of this data. The rest are in low-income countries, 77% of which are in sub-Saharan Africa. Perinatal mortality rates for sub-Saharan Africa and Zambia are 42.95 and 33/1000 live births, respectively. The aim of this study was to determine the predictors of perinatal mortality at the seven major hospitals of Lusaka, Zambia.
Methods This was a multi- centre unmatched case control study from September 2023 to January 2024. Cases included perinatal death (>24 weeks gestation or >500g stillborn, and death of neonate within seven days of life) and controls were live births. Stepwise multivariate logistic regression analysis determined predictors using adjusted odd ratios and p-values.
Results The study had 630 participants, 210 cases and 420 controls were analysed: ratio 1:2. Antenatal care booking after 12 weeks gestation had almost three times odds of experiencing perinatal (AOR 2.909, 95% CI: 1.97-4.296), p <0.001 compared to those who booked early. Walking as means of reaching healthcare facility had over three odds perinatal mortality (AOR3.482, 95% CI: 1.87-6.49) than personal transport users. Anaemia during pregnancy had over three times risk of perinatal death (AOR 3.581, 95% CI: 1.72- 7.44) than those without it. History of loss of baby before birth had five fold odds to experience perinatal mortality than to those who had not (AOR 5.047, 95% CI: 2.99-8.51).
Conclusion This study revealed that late antenatal care booking, walking, as means of transport to access health facility, anaemia in pregnancy, and previous history of loss of baby before birth perinatal death were the main predictors with statistical significance of perinatal death experience.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We declare that this project has not had any commercial funding or grant from any funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for this study was through the University of Zambia Biomedical Research Ethics Committee (Unzabrec) (referee 3718-2023). This followed clearance by the National Health Research Authority (NHRA) reference number NHRA 000012/16/03/2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
We will make full availability and without restriction all data underlying the findings if requested
